{"product_id":"teva-five-forces","title":"(TEVA) Teva Pharmaceutical Industries Limited Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Teva Pharmaceutical Industries Limited Porter's Five Forces Analysis helps you assess rivalry, buyer power, supplier power, substitutes, and new entrants. This page already shows a real preview of the report, so you can review the content before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized API inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited reported $16.5 billion in 2024 revenue, but it still depends on outside suppliers for some specialty raw materials and complex API inputs. For hard-to-make molecules, GMP-certified sources are limited and switching can take months, so suppliers can push price and lead-time terms. Teva sells APIs too, but scarcity and tight regulation keep supplier power meaningful.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSterile and biologics materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited’s sterile injectables, inhalation products, and long-acting formulations depend on GMP-grade materials and packaging from a narrow supplier base. That raises supplier power, because any miss in quality or delivery can halt batches, delay releases, and trigger compliance risk. This is a harder sourcing setup than basic generics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-source dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited still has some manufacturing lines tied to single or narrow-source suppliers for key inputs, so one price hike or shortage can hit several products at once. In 2025, that concentration kept switching costs high and short-term backup options limited. That gives suppliers stronger pricing power in selected categories, especially for critical components.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory qualification burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited faces high supplier power here because a new source cannot be swapped in fast: each change can need validation, audits, and regulatory filings. In pharma, that slows renegotiation and makes already qualified suppliers more valuable than in less regulated sectors. When a switch can take 3 steps before use, incumbents keep pricing leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValidation slows supplier replacement.\u003c\/li\u003e\n\u003cli\u003eAudits add time and cost.\u003c\/li\u003e\n\u003cli\u003eFilings delay faster sourcing.\u003c\/li\u003e\n\u003cli\u003eQualified suppliers hold more power.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScale offsets supplier power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited’s scale keeps supplier power moderate: it reported about \"$16.5 billion\" in 2024 revenue, so it can spread purchases across a large, diversified portfolio of generics and specialty drugs. Long-term contracts and multi-site sourcing cut dependence on any one input maker, while volume gives Teva better pricing than smaller peers. Still, active ingredients remain a real risk, so suppliers are not weak, just constrained.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge volume improves pricing power.\u003c\/li\u003e\n\u003cli\u003eMultiple sites reduce single-source risk.\u003c\/li\u003e\n\u003cli\u003eBroad portfolio lowers supplier leverage.\u003c\/li\u003e\n\u003cli\u003eSupplier power stays moderate, not extreme.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva Faces Moderate-High Supplier Power in Key Inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited faces moderate to high supplier power because GMP-grade APIs, sterile inputs, and packaging come from a narrow pool, and switching can take months of validation and filings. Its $16.5 billion 2024 revenue and broad sourcing help offset some leverage, but single-source inputs still raise price and delay risk. Supplier power is strongest in complex, regulated products and weaker in commoditized generics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$16.5 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching time\u003c\/td\u003e\n\u003ctd\u003eMonths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier concentration\u003c\/td\u003e\n\u003ctd\u003eNarrow in key inputs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePower level\u003c\/td\u003e\n\u003ctd\u003eModerate to high\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAssesses Teva Pharmaceutical Industries Limited’s competitive pressures from rivals, suppliers, buyers, new entrants, and substitutes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly spot Teva’s competitive pressures in one clear snapshot—saving time on strategic analysis and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Teva, helping users verify key assumptions fast and make better decisions with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge buyers dominate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva sells through wholesalers, pharmacy chains, hospitals, and government-linked buyers, and these channels buy in huge lots. In 2025, that means a few large customers can concentrate demand and push for lower prices, shorter terms, and rebates. Their scale gives them strong bargaining power, especially in commoditized generics where switching costs are low.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric pricing pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited faces heavy bargaining power from customers because much of its portfolio sits in generic drugs, where buyers can compare FDA-approved suppliers fast and switch when quality and supply match. In the U.S., generics fill about 90% of prescriptions but make up only about 15% of drug spending, so price pressure is intense. That keeps Teva’s margins tight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBMs and tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBMs and tender buyers hold strong bargaining power because they steer access and reimbursement, then push the lowest net cost. In the U.S., the 3 biggest PBMs manage about 80% of prescriptions, so Teva has to match steep rebates and tight contract terms to win volume. In many tenders, a few winners can take most share fast, which keeps pricing pressure high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLimited brand loyalty in many products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited faces high buyer power because once a generic proves therapeutic equivalence, switching costs are near zero and loyalty fades fast. In 2025, Teva still relied on roughly $16 billion in net sales, much of it exposed to price pressure from large buyers that can move volume to rival suppliers.\u003c\/p\u003e\n\u003cp\u003eEven Teva’s branded specialty drugs face payer controls, prior authorization, and formulary pressure, which weakens pricing power. So customers can demand discounts, exclude products, or shift share quickly if Teva does not offer the best net price or access terms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGeneric buyers switch on price, not brand.\u003c\/li\u003e\n\u003cli\u003ePayers can block or delay access.\u003c\/li\u003e\n\u003cli\u003eLow loyalty raises discount pressure.\u003c\/li\u003e\n\u003cli\u003eCustomer bargaining power stays high.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCritical therapies provide some cushion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited has weaker customer power in critical therapies because some products are more differentiated in multiple sclerosis, migraine prevention, respiratory care, and oncology. In these niches, outcomes, device format, and supply reliability matter more than price, so buyers have less room to push back. That helps Teva protect pricing in parts of a 2024 revenue base of about $16.5 billion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDifferentiation cuts buyer leverage.\u003c\/li\u003e\n\u003cli\u003eReliability can outweigh price.\u003c\/li\u003e\n\u003cli\u003eSpecialty drugs support pricing power.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva Faces Heavy Buyer Power in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited faces high customer bargaining power in 2025 because large PBMs, wholesalers, hospitals, and tender buyers control access and can force rebates, discounts, and tight terms. In generics, switching costs are near zero, so price matters more than brand. Teva’s 2025 net sales were about $16 billion, but buyer concentration keeps net pricing under pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e$16.0bn\u003c\/td\u003e\n\u003ctd\u003eScale still meets price pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. generic share\u003c\/td\u003e\n\u003ctd\u003e~90% prescriptions\u003c\/td\u003e\n\u003ctd\u003eSwitching is easy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. generic spend share\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003ctd\u003eBuyers push prices down\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop PBMs\u003c\/td\u003e\n\u003ctd\u003e~80% of prescriptions\u003c\/td\u003e\n\u003ctd\u003eStrong buyer concentration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTeva Pharmaceutical Industries Limited Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Teva Pharmaceutical Industries Limited Porter's Five Forces Analysis you’ll receive after purchase—no mockups, no placeholders, just the full document. It’s professionally written, clearly formatted, and ready for immediate use as soon as your payment is complete. What you see here is the same file you’ll be able to download, so you can buy with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense generic competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva competes in crowded generic markets where many firms can sell the same molecules, and U.S. generics still make up about 90% of prescriptions but only 17% of drug spending. Rivalry is driven by price cuts, supply reliability, and tender wins, so margins stay thin. That keeps competitive pressure strong and persistent.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty peer competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited’s specialty drugs face intense rivalry from large pharma and biosimilar makers, especially in migraine, multiple sclerosis, and respiratory care. Teva reported about $16.6 billion in 2024 revenue, and competition stays sharp because rivals push hard and doctors switch products often. In these categories, high sales pressure keeps pricing and market share under strain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent expiries create churn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWhen branded drugs lose exclusivity, copycat makers rush in, and prices often drop 80% to 90% within months. Teva Pharmaceutical Industries Limited benefits when it launches generics, but it also faces the same churn when rivals enter fast. U.S. generics make up about 90% of prescriptions but only 18% of spending, showing how quickly patent expiries drive share shifts and margin pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScale and supply reliability matter\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompetitive rivalry is high because buyers value dependable manufacturing and broad distribution, not just low list prices. Teva’s scale matters here: in 2024, the Company generated about $16.5 billion in net sales and kept investing in quality and compliance to protect access with large customers. In generics, a missed shipment can lose a contract fast, so rivalry runs on service, supply reliability, and price.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScale helps win supply contracts.\u003c\/li\u003e\n\u003cli\u003eReliability can beat lower prices.\u003c\/li\u003e\n\u003cli\u003eQuality and compliance need constant spend.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePortfolio breadth partially balances rivalry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited’s broad mix in generics, specialty medicines, and active pharmaceutical ingredients helps cushion any one weak line, but rivals still hit each segment hard. In 2025, Teva reported about $15.8 billion in revenue, yet pricing pressure and fast generic launches kept rivalry intense. That makes competition one of Teva’s strongest forces.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad portfolio softens single-segment shocks\u003c\/li\u003e\n\u003cli\u003eRivals compete product by product\u003c\/li\u003e\n\u003cli\u003e2025 revenue was about $15.8 billion\u003c\/li\u003e\n\u003cli\u003eOverall rivalry stays very high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva Faces Intense Rivalry as Price Wars Pressure Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry at Teva Pharmaceutical Industries Limited stays high: 2025 net sales were about $15.8 billion, but generics are still a price war, and U.S. generics account for about 90% of prescriptions and only 18% of drug spending. Branded rivals in migraine, MS, and respiratory care also press hard, so share can shift fast when doctors switch.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTeva net sales\u003c\/td\u003e\n\u003ctd\u003e$15.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. generics share\u003c\/td\u003e\n\u003ctd\u003e90% Rx \/ 18% spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRivalry level\u003c\/td\u003e\n\u003ctd\u003eVery high\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlternative therapies are a real threat for Teva Pharmaceutical Industries Limited because patients and prescribers can switch across drug classes for migraine, asthma, pain, and CNS care. Migraine affects about 1 billion people worldwide, and asthma about 262 million, so even small shifts to competing therapies can move large volumes. This keeps pricing power limited and makes differentiation critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-drug interventions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNon-drug options pressure Teva Pharmaceutical Industries Limited in markets where lifestyle change, devices, behavioral therapy, and procedures can cut drug use. WHO says 1.4 billion adults were insufficiently active, and that trend supports more prevention-led care that can trim prescription volume in obesity, diabetes, pain, and sleep disorders. These are not full replacements everywhere, but in selected indications they reduce repeat fills and narrow Teva Pharmaceutical Industries Limited’s addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars and alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiosimilars and branded rivals pressure Teva Pharmaceutical Industries Limited in biologic and specialty drugs, where payers often switch to lower-cost options. In the U.S., the FDA had approved 60+ biosimilars by 2025, and the EU had 100+ approvals, widening substitution risk. That caps Teva Pharmaceutical Industries Limited’s pricing power and can force heavier rebates to win coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFormulary-driven switching\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFormulary-driven switching is a real threat for Teva Pharmaceutical Industries Limited because payers can steer patients to preferred drugs through formulary and reimbursement rules, even when Teva’s medicine is clinically equal. The three biggest U.S. pharmacy benefit managers still control about 80% of prescriptions, so access can shift fast without a medical reason. Teva has to win placement as much as efficacy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eAccess can beat clinical parity.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePBMs can switch volume administratively.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePreferred-tier status protects share.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eRebates and net price matter most.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSeverity and device format reduce substitution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited’s substitution threat is lower in niches where treatment is chronic or severe and the dosage form is hard to copy. Inhalers, injectables, and long-acting drugs are less like a pill and more like a device, which raises switching friction for doctors and patients.\u003c\/p\u003e\n\u003cp\u003eThat matters in respiratory and oncology care, where correct delivery can drive outcomes. Teva’s 2024 net sales were about $16.5 billion, and branded specialty products help keep some of this mix harder to replace.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChronic and serious cases raise switching costs\u003c\/li\u003e\n\u003cli\u003eDevice formats limit easy pill substitution\u003c\/li\u003e\n\u003cli\u003eSpecialty products weaken generic pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva Faces Rising Substitute Pressure Across Drug Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is high for Teva Pharmaceutical Industries Limited because patients, doctors, and payers can shift to rival drugs, biosimilars, devices, or non-drug care. FDA biosimilar approvals topped 60 by 2025, and PBMs can steer volume fast. Teva Pharmaceutical Industries Limited’s 2024 net sales were about $16.5 billion, so even small share losses matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003ePressure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003e60+ FDA approvals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM switching\u003c\/td\u003e\n\u003ctd\u003e~80% U.S. scripts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-drug care\u003c\/td\u003e\n\u003ctd\u003e1.4B inactive adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegulatory barriers are a major wall for new drug makers: a U.S. FDA approval can take about 10-12 years and often cost over $1 billion, while each site must pass inspections and maintain pharmacovigilance systems. Teva Pharmaceutical Industries Limited already operates under this high-cost rule set, so newcomers face slow launch timing and higher failure risk. That makes new entry structurally hard, especially in generics and complex medicines, where compliance is constant and lapses can trigger recalls, fines, or shutdowns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital and manufacturing scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries Limited’s scale in complex generics, sterile plants, and global distribution makes entry expensive. Teva reported about $16.5 billion in net sales in 2024, showing the size needed to compete. New entrants must fund multi-year buildouts, validation, and quality systems before they can ship at scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality and reputation hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuality and reputation are major entry barriers in generics and specialty pharma. Buyers and regulators watch recalls, FDA Form 483s, and supply hits closely, so new entrants without a clean track record can lose formulary access and contracts fast. Teva’s scale and long operating history help it stand out versus smaller rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP and litigation risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIP disputes lift the entry bar for Teva Pharmaceutical Industries Limited. In the U.S., a patent challenge can trigger a 30-month stay under Hatch-Waxman, and first generic filers may face 180-day exclusivity fights, so launch timing can slip and legal spend rises fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30-month stay delays entry\u003c\/li\u003e\n\u003cli\u003e180-day exclusivity creates barriers\u003c\/li\u003e\n\u003cli\u003ePatent suits add legal cost\u003c\/li\u003e\n\u003cli\u003eHigher entry cost lowers threat\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNiche entrants remain possible\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmall firms can still enter narrow generic and development niches by outsourcing manufacturing and focusing on a few products. Biosimilar and specialty start-ups also target selected openings, but they usually lack Teva Pharmaceutical Industries Limited's scale, broad portfolio, and market reach. So the threat of new entrants is real, but moderate, not high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOutsourced production lowers entry costs.\u003c\/li\u003e\n\u003cli\u003eNiche portfolios can bypass broad scale needs.\u003c\/li\u003e\n\u003cli\u003eBiosimilars open selective entry points.\u003c\/li\u003e\n\u003cli\u003eTeva's large scale still raises barriers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva’s High Bar Keeps Most New Entrants Out\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for Teva Pharmaceutical Industries Limited is moderate. The FDA path can take 10-12 years and cost over $1 billion, while patent fights can add a 30-month stay and 180-day exclusivity delays. Teva Pharmaceutical Industries Limited's $16.5 billion net sales in 2024 show the scale newcomers need, so only niche or outsourced players can enter with ease.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA approval time\u003c\/td\u003e\n\u003ctd\u003e10-12 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment cost\u003c\/td\u003e\n\u003ctd\u003eOver $1 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent stay\u003c\/td\u003e\n\u003ctd\u003e30 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTeva net sales\u003c\/td\u003e\n\u003ctd\u003e$16.5 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235065929993,"sku":"teva-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/teva-five-forces.webp?v=1785733429","url":"https:\/\/dcfanalyst.com\/products\/teva-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}